# Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer

> **NCT01232881** · — · TERMINATED · sponsor: **Hoosier Cancer Research Network** · enrollment: 27 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **PROCEDURE:** Tumor Sample
- **PROCEDURE:** Serum Sample

## Key facts

- **NCT ID:** NCT01232881
- **Lead sponsor:** Hoosier Cancer Research Network
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2009-08
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** funding terminated
- **Last updated:** 2011-04-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01232881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01232881, "Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01232881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*